Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Altamira Therapeutics ( (CYTOF) ).
On March 4, 2025, Altamira Therapeutics Ltd. and Altamira Medica AG amended their Framework Agreement, resulting in Altamira Therapeutics waiving its right to 25% of future licensing revenues from Bentrio®. However, Altamira Therapeutics retains its entitlement to 25% of proceeds exceeding the majority owner’s cash contribution from any sale or transfer of Medica to a third party. This strategic move may impact Altamira’s revenue streams and reflects a shift in their financial arrangements with Medica.
More about Altamira Therapeutics
Altamira Therapeutics Ltd. operates in the medical devices industry, focusing on the development and commercialization of products such as Bentrio®. The company holds a 49% stake in Altamira Medica AG, which is involved in licensing these medical devices.
YTD Price Performance: -17.21%
Average Trading Volume: 61,274
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $382K
Learn more about CYTOF stock on TipRanks’ Stock Analysis page.